2013-01-05 : Smaller Pen Needle Makes Insulin Injections Less Painful

Shenzhen, January 5th, 2013 - CONTINUUM Healthcare Co. Ltd reminds diabetic people that Injecting insulin just got a little easier with the introduction of their 32G and 33G 4mm insulin pen needles which competes with the thinnest and shortest needles on the market from the main players but just for a fraction of their price.

Recent studies have shown that insulin injections with these new short and fine pen needles are just as effective in the delivery of insulin. Clinical trials have shown that insulin injected in subcutaneous tissue (the layer of fat below the skin) is absorbed more gradually and is more effective at reducing the risk of hypoglycemia (low blood sugar) than deeper muscle injections.

The reliability and quality of our diabetes product line has been proven for several years throughout our sales in Europe. Therefore we encourage diabetic specialized companies to get in touch with us to work on OEM with their labels, and confidently promote on their own market, by then increasing their own profit while confidently growing their notoriety.

Do not hesitate to contact us for volume purchase and customized packaging.

CONTINUUM Healthcare Co. Ltd, rather known under AMBISEA Technology Corp., Ltd, its Hong Kong based sister company, is a respected name in the health care industry. It is an ISO13485 Certified company whose main concerns are manufacturing portable medical devices and disposable items for the health care segment. The company’s high quality, low priced products have managed to create a steady stream of loyal customers and on their popular demand it has now launched a new range of high quality disposables meant to help the diabetes patients. CONTINUUM welcomes OEM/ODM inquiries from distributors, wholesalers and retailers worldwide.

# # #
To gain additional information on the products, please visit our website www.continuum.cn or www.ambisea.com, you could also email Mr Stephane Hollande, in charge of Business Development at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call CONTINUUM office +86 755 2647 5192.

Source: AMBISEA Technology Corp., Ltd.